



Deadline	<b>Wed 07 Mar 2018 17:00 CET Pre-proposals</b> <b>Thu 14 Jun 2018 17:00 CET Full-proposals</b>
Call name	<b>Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) - Innovations against antibiotic-resistant bacteria: new targets, compounds and tools</b>
www	JPIAMR: <a href="https://www.jpiamr.eu/6thcall/">https://www.jpiamr.eu/6thcall/</a> MEYS (MŠMT): <a href="http://www.msmt.cz/vyzkum-a-vyvoj-2/iniciativa-spolecneho-programovani-antimikrobialni-1">http://www.msmt.cz/vyzkum-a-vyvoj-2/iniciativa-spolecneho-programovani-antimikrobialni-1</a>
Focused on	Fundamental, translation research, with exception of clinical trials
PI	Consortium of 3–6 (7) partners (senior researchers, junior researchers, postdocs) represented by a coordinator
Eligible organisation	Research organisations / public higher education institutions / national restriction may apply to Private sector and SMEs Participating country: Belgium, Czech Republic, Egypt, Finland, France, Germany, Ireland, Israel, Italy, Latvia, Norway, Poland, Romania, Spain, Sweden and Switzerland
Target group	Multinational research groups collaboration: Consortium from min. 3 countries, with participation of 3–6 (with CZ participation up to 7) partners, national limits on number partner/consortium (CZ limit max.2)
Expected outputs	Not specified
Call opens	Thu 11 Jan 2018
IOCB deadline	<b>Mon 05 Mar 2018 Pre-proposals</b> <b>Tue 12 Jun 2018 Full-proposals</b>
Final deadline	<b>Wed 07 Mar 2018 17:00 CET Pre-proposals</b> One joint proposal per consortium- submission website: <a href="https://secure.pt-dlr.de/ptoutline/app/jpiamr2018">https://secure.pt-dlr.de/ptoutline/app/jpiamr2018</a> Czech participant: MEYS: both by electronic correspondence ( <a href="mailto:daniel.hanspach@msmt.cz">daniel.hanspach@msmt.cz</a> ) and post (one signed and stamped hard copy) <b>Thu 14 Jun 2018 17:00 CET Full-proposals</b> same as pre-proposals
Evaluation results	October/November 2018
Signature of agreement	
Earliest date of implementation	End of 2018/Early 2019
Latest date of implementation	
Sustainability	none
Reporting	national rules (for Czech participants – MEYS, annual reports 31 January)
Project duration (min-max)	<b>up to 36 months</b>
Allocation for the call	Total 14.4 M EUR, MEYS 0.25 M EUR
Project budget (min-max)	No max. limit
Success rate	? %
Eligible costs	Czech participant: §2 of the Act. No 130/2002 Coll. direct costs: personnel, consumables, equipment, travel, other costs indirect costs: overheads max 25 % (fat rate) of direct costs without subcontracting
Reimbursement	100 % for fundamental/basic research activities, 50 % for applied research activities and 25 % for experimental development activities
Mode of funding	ex-ante
Language of application	English/Czech for MEYS

Provider	<p>Consortium of providers from 16 countries (for Czech participants – MEYS)  Ministry of Education, Youth and Sports of the Czech Republic (MEYS/MŠMT), Prague,  <a href="http://www.msmt.cz">www.msmt.cz</a>  Mgr. Daniel Hanšpach, +420 234 811 360, <a href="mailto:daniel.hanspach@msmt.cz">daniel.hanspach@msmt.cz</a>  Joint Call secretariat: The French National Research Agency (ANR), <a href="http://www.jpiamr.eu/6thcall/">www.jpiamr.eu/6thcall/</a>  Martine Batoux or Virginie Mouchel, +33 (0)178 098 044, <a href="mailto:JPI-AMRCalls@agencerecherche.fr">JPI-AMRCalls@agencerecherche.fr</a></p>
Call identifier	JPIAMR 2018
Conditions / Restrictions	<p>The proposal should address at least one of the following topics:</p> <p><b>New targets:</b> Studies of new bacterial targets or mechanisms of resistance (examples include studies on novel enzyme or efflux pump inhibitors or others), including studies aimed at understanding and overcoming the mechanisms controlling the generation of resistance.</p> <p><b>New therapies:</b> Discovery of new compounds (including new antibiotics and alternatives); Strategies to inhibit or reduce the acquisition of resistance, such as single molecular agents effective against multiple targets as well as therapeutics that enhance immune-mediated pathogen elimination, disrupt colonisation or biofilm development, and reduce virulence; Discovery of novel therapies to overcome known antimicrobial resistance mechanisms and/or to restore susceptibility to conventional antibiotics.</p> <p><b>New tools/assays:</b> Strategies and/or innovative tools or assays that improve, enhance, and/or facilitate the identification or validation of new effective compounds or therapies; Strategies and/or innovative tools for optimization of drug use, dosage and delivery of new drugs; Exploration of bacterial genes e.g. expression of latent gene clusters</p> <p><b>The following sub-topics are not within the scope of the call:</b> Investigations addressing cross-talk between the host and pathogen, as well as the relationship between microbes, environment and infection; Studies on bacteria not in the WHO Global priority list above; Investigations on the initial steps of the infection process; Investigations based on, or involving, clinical trials; Re-evaluation of existing anti-microbial compounds in the context of their combination with new, innovative targets, compounds; or tools.</p>
Proposal consists of	<p>Joint pre-proposal application form (description of the project - 5 pp.; work plan, timeline, work flow - 1p.; CV of each PI – 1 p.; budget table, etc.)  MEYS requested documentation: Eligible Costs Specification and Statutory Declaration</p>
Evaluation criteria	<p>1) Excellence; 2) Impact; 3) Quality and efficiency of the implementation  Maximum score 15 points; threshold for individual criteria – 3 points</p>
Research areas	<p>Support only for studies on bacteria in the WHO Global priority list of antibiotic-resistant bacteria:</p> <ul style="list-style-type: none"> <li>- <i>Mycobacterium tuberculosis</i>; multi-and extensively drug resistant</li> <li>- <i>Acinetobacter baumannii</i>; carbapenem-resistant</li> <li>- <i>Pseudomonas aeruginosa</i>; carbapenem-resistant</li> <li>- <i>Enterobacteriaceae</i> (<i>Klebsiella pneumoniae</i>, <i>Escherichia coli</i>, <i>Enterobacter</i> spp., <i>Serratia</i> spp., <i>Proteus</i> spp., <i>Providencia</i> spp. and <i>Morganella</i> spp.); carbapenem-resistant, 3rd generation cephalosporin-resistant</li> <li>- <i>Enterococcus faecium</i>; vancomycin-resistant</li> <li>- <i>Staphylococcus aureus</i>; methicillin-resistant, vancomycin intermediate and resistant</li> <li>- <i>Helicobacter pylori</i>; clarithromycin-resistant</li> <li>- <i>Campylobacter</i>; fluoroquinolone-resistant</li> <li>- <i>Salmonella</i> spp.; fluoroquinolone-resistant</li> <li>- <i>Neisseria gonorrhoeae</i>; 3rd generation cephalosporin-resistant, fluoroquinolone-resistant</li> <li>- <i>Streptococcus pneumoniae</i>; penicillin-non-susceptible</li> <li>- <i>Haemophilus influenzae</i>; ampicillin-resistant</li> <li>- <i>Shigella</i> spp.; fluoroquinolone-resistant</li> </ul>
Call workshop	<p><b>Wed 21 Feb 2018, Prague, Technology Centre of the CAS</b>  (registration till February 19, 2018 <a href="http://zde">zde</a>)  <b>Workshop: Proposal writing for H2020: ICT and Health</b></p>
IOCB contact	<p>We kindly ask the serious applicants to inform IOCB Grant Centre / Project Office asap.  Thank you very much. We are looking forward to supporting your project and to helping with preparation of your grant application.  Veronika Palečková, <a href="mailto:veronika.paleckova@uochb.cas.cz">veronika.paleckova@uochb.cas.cz</a>, +420 220 183 266  Jitka Šilerová, <a href="mailto:jitka.silerova@uochb.cas.cz">jitka.silerova@uochb.cas.cz</a>, +420 220 183 229</p>
Download documents	<p>2018-01-11_IOCB_call_JPIAMR-2018_D2018-03-07  JPIAMR_2018_Call  JPIAMR_2018_Pre-proposal-template  JPIAMR_2018_MSMT_Eligibility criteria  JPIAMR_2018_MSMT_Budget</p>

--	--